10x Genomics Stock Performance
| TXG Stock | USD 18.61 0.91 5.14% |
On a scale of 0 to 100, 10X Genomics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.32, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 10X Genomics will likely underperform. Please check 10X Genomics' maximum drawdown, expected short fall, as well as the relationship between the Expected Short fall and rate of daily change , to make a quick decision on whether 10X Genomics' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in 10X Genomics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, 10X Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.14 | Five Day Return (7.87) | Year To Date Return 11.97 | Ten Year Return (64.72) | All Time Return (64.72) |
Last Split Factor 1:2 | Last Split Date 2006-07-17 |
1 | Will 10x Genomics Flex Assay Shift the Balance Between Innovation and Revenue Stability | 11/12/2025 |
2 | 10x Genomics Stock Trades Up, Here Is Why | 12/22/2025 |
3 | Assessing 10x Genomics Valuation After Recent Share Price Momentum Shift | 01/09/2026 |
4 | 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease | 01/12/2026 |
5 | 1 Cash-Heavy Stock to Consider Right Now and 2 We Question | 01/13/2026 |
6 | Inscription Capital LLC Acquires 59,305 Shares of 10x Genomics TXG - MarketBeat | 01/21/2026 |
7 | Assessing 10x Genomics Valuation After Recent Share Price Momentum | 01/23/2026 |
8 | 3 Small-Cap Stocks Were Skeptical Of | 01/26/2026 |
9 | Foundations Investment Advisors LLC Takes Position in 10x Genomics TXG - MarketBeat | 02/02/2026 |
10 | 10x Genomics May Report Negative Earnings Know the Trend Ahead of Next Weeks Release - Yahoo Finance Canada | 02/05/2026 |
| Begin Period Cash Flow | 359.3 M | |
| Total Cashflows From Investing Activities | -32.6 M |
10X Genomics Relative Risk vs. Return Landscape
If you would invest 1,708 in 10X Genomics on November 9, 2025 and sell it today you would earn a total of 153.00 from holding 10X Genomics or generate 8.96% return on investment over 90 days. 10X Genomics is generating 0.2134% of daily returns assuming volatility of 3.8853% on return distribution over 90 days investment horizon. In other words, 34% of stocks are less volatile than 10X, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
10X Genomics Target Price Odds to finish over Current Price
The tendency of 10X Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 18.61 | 90 days | 18.61 | about 39.85 |
Based on a normal probability distribution, the odds of 10X Genomics to move above the current price in 90 days from now is about 39.85 (This 10X Genomics probability density function shows the probability of 10X Stock to fall within a particular range of prices over 90 days) .
10X Genomics Price Density |
| Price |
Predictive Modules for 10X Genomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as 10X Genomics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of 10X Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
10X Genomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. 10X Genomics is not an exception. The market had few large corrections towards the 10X Genomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold 10X Genomics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of 10X Genomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.45 | |
β | Beta against Dow Jones | 1.32 | |
σ | Overall volatility | 2.41 | |
Ir | Information ratio | 0.10 |
10X Genomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of 10X Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for 10X Genomics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| 10X Genomics had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 442.49 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Gaugh David Russell of 6304 shares of Amphastar subject to Rule 16b-3 |
10X Genomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of 10X Stock often depends not only on the future outlook of the current and potential 10X Genomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. 10X Genomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 120.5 M | |
| Cash And Short Term Investments | 393.4 M |
10X Genomics Fundamentals Growth
10X Stock prices reflect investors' perceptions of the future prospects and financial health of 10X Genomics, and 10X Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 10X Stock performance.
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.0842 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 2.02 B | ||||
| Shares Outstanding | 116.47 M | ||||
| Price To Book | 3.08 X | ||||
| Price To Sales | 3.49 X | ||||
| Revenue | 610.78 M | ||||
| Gross Profit | 442.49 M | ||||
| EBITDA | (133.99 M) | ||||
| Net Income | (182.63 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 82.61 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 6.21 X | ||||
| Cash Flow From Operations | 6.66 M | ||||
| Earnings Per Share | (0.58) X | ||||
| Market Capitalization | 2.24 B | ||||
| Total Asset | 918.64 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 466.75 M | ||||
About 10X Genomics Performance
By analyzing 10X Genomics' fundamental ratios, stakeholders can gain valuable insights into 10X Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if 10X Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 10X Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 139.07 | 138.06 | |
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.30) | (0.28) |
Things to note about 10X Genomics performance evaluation
Checking the ongoing alerts about 10X Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 10X Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 10X Genomics had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 442.49 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Gaugh David Russell of 6304 shares of Amphastar subject to Rule 16b-3 |
- Analyzing 10X Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 10X Genomics' stock is overvalued or undervalued compared to its peers.
- Examining 10X Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 10X Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of 10X Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 10X Genomics' stock. These opinions can provide insight into 10X Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |